Literature DB >> 8647170

Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock.

R S Yeung1, J M Penninger, T Kündig, W Khoo, P S Ohashi, G Kroemer, T W Mak.   

Abstract

Rodents are significantly less sensitive to enterotoxin-induced shock, and are thus not valid human disease models. Here, we describe a mouse strain carrying the human CD4 and human major histocompatibility complex (MHC) class II (DQ6) transgenes in an endogenous CD4- and CD8-deficient background. T lymphocytes from these animals react to minute amounts (10-100 times less than control mice) of staphylococcal enterotoxin B (SEB) in vitro, similar to concentrations to which human cells react. In vivo, these double-transgenic, double-knockout mice succumb to normally sublethal amounts of SEB. This sensitivity is not due to a biased T cell receptor V beta repertoire, increased T cell reactivity, or increased sensitivity to macrophage-derived cytokines. Rather, tumor necrosis factor (TNF)-alpha production by T cells and serum levels of TNF-alpha correlate precisely with the clinical syndrome, showing a biphasic T cell-dependent response. These data show that both human CD4 and MHC class II molecules can render mice supersensitive to superantigen-induced septic shock syndrome. This animal model mimics the progression of septic shock in man by transforming normally resistant mice into hypersensitive SEB responders, a trait that is characteristic of humans. Mice that have been humanized by exchanging autochthonous superantigen ligands by their human equivalents may be useful to decipher superantigen responses in vivo and to assess the pathogenesis of superantigen-associated diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647170     DOI: 10.1002/eji.1830260518

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  23 in total

1.  Endogenous superantigens shape response to exogenous superantigens.

Authors:  Govindarajan Rajagopalan; Manisha Singh; Moon M Sen; Narayana S Murali; Karl A Nath; Chella S David
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

2.  In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists.

Authors:  Govindarajan Rajagopalan; Moon M Sen; Chella S David
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

3.  Acute systemic immune activation following conjunctival exposure to staphylococcal enterotoxin B.

Authors:  Govindarajan Rajagopalan; Michele K Smart; Robin Patel; Chella S David
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

4.  Genetically engineered superantigens as tolerable antitumor agents.

Authors:  J Hansson; L Ohlsson; R Persson; G Andersson; N G Ilbäck; M J Litton; T Kalland; M Dohlsten
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

5.  Comparative analysis of lipopolysaccharide-induced tumor necrosis factor alpha activity in serum and lethality in mice and rabbits pretreated with the staphylococcal superantigen toxic shock syndrome toxin 1.

Authors:  M M Dinges; P M Schlievert
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Production of tumor necrosis factor alpha in human T lymphocytes by staphylococcal enterotoxin B correlates with toxin-induced proliferation and is regulated through protein kinase C.

Authors:  Z Yan; D C Yang; R Neill; M Jett
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

7.  Staphylococcal enterotoxin B in vivo modulates both gamma interferon receptor expression and ligand-induced activation of signal transducer and activator of transcription 1 in T cells.

Authors:  R Plaza; J L Rodriguez-Sanchez; C Juarez
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

8.  Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo.

Authors:  Teresa Krakauer; Marilyn Buckley; Haleem J Issaq; Stephen D Fox
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 9.  Models matter: the search for an effective Staphylococcus aureus vaccine.

Authors:  Wilmara Salgado-Pabón; Patrick M Schlievert
Journal:  Nat Rev Microbiol       Date:  2014-07-07       Impact factor: 60.633

10.  Blocking TNF-alpha attenuates aneurysm formation in a murine model.

Authors:  Wanfen Xiong; Jason MacTaggart; Rebecca Knispel; Jennifer Worth; Yuri Persidsky; B Timothy Baxter
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.